http://dx.doi.org/10.31703/giidr.2021(VI-II).05
10.31703/giidr.2021(VI-II).05
Published : Dec 2021
Hepatocellular Carcinoma: From Epidemiology to Advancement in Treatment
Hepatocellular carcinoma is a heterogenous malignant tumor that is known as the deadliest cancer worldwide due to its complexities. Most of the time, it occurs with underlying liver complications, including cirrhosis. The most predominant risk factors in HCC development are cirrhosis and chronic Hepatitis B virus (HBV) infection. Its complexities pose multiple challenges in diagnostic and therapeutic measures. In recent years, a huge rise in cases is seen in non-traditional countries such as North America and European regions rather than Japan and China. Herein, our aim is to give an overview of the latest information about hepatocellular carcinoma regarding its epidemiology, risk factors, biomarkers, staging, diagnosis, and treatment.
-
Hepatocellular Carcinoma, Epidemiology, Risks, Staging Systems, Treatment
-
(1) Amber Sani
Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
(2) M. Khalil-ur-Rehman
Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
(3) Aqsa Saleem Raza
Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
(4) Muhammad Khalid Tipu
Assistant Professor, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
- Aitcheson, G., & Pillai, A. et al, (2021). Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma, Current Hepatocellular Reports, Springer, vol (20), page (23-33)
- Anwar, S. L., & Lehmann, U. (2014). DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol 20,7894- 7913
- Bartolozzi, C., Lencioni, R., & Caramella, D. et al. Small hepatocellular carcinoma. Detection with US, CT, MR imaging, DSA, and Lipiodol- CT. Acta Radiol1996 37, 69-74.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
- Chaiteerakij, R., Addissie, B. D., & Roberts, L. R. (2015). Perspectives in clinical gastroenterology and hepatology, 13, 235-245
- Daher, S., & Massarwa, M. et al, (2017). Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review, Journal of Clinical and Translational Hepatology, Jerusalem, Israel, vol (6), page (69-78)
- Dutta, R., Mahato, R. I. (2017). Recent Advances in Hepatocellular Carcinoma Therapy, Pharmacology and Therapeutics, US, Elsevier, vol (173), page (106-117)
- EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma, Journal of Hepatology, (2018).
- Ferlay, J., Ervik, M., & Lam, F. et al., (2018). Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer
- Gelu-Simeon, M., Sobesky, R., & Haim-Boukobza, S. et al., (2014). Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies? AIDS
- GLOBOCAN. (2012,2013). Cancer Incidence and Mortality Worldwide: IARC . International Agency for Research on Cancer v1.0.
- Graf, D., & Vallbohmer, D. (2014). Multimodal Treatment of Hepatocellular Carcinoma, European Journal of Internal Medicine, Elsevier, Germany, Vol (25), page (430-437)
- Greten, T. F., Lai, C. W., & Li, G. et al, (2018). Targeted and Immune-Based Therapies for Hepatocellular Carcinoma, Gastroenterology.
- Haung, A., Yang, X. R., & Chung, W. Y. et al, (2020). Targeted Therapy for Hepatocellular Carcinoma, Signal Transduction and Targeted Therapy, Nature. China
- Hite, D. L., Kanwal, F., & El-Serag, H. B. (2012). Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol
- Ji, J., Sundquist, K., & Sundquist, J. (2012). A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma
- Koulouris, A., Tsagkaris, C., & Pappa, E. et al, (2021). Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options, Journal of Hepatocellular Carcinoma, vol (8), page (387-401), Greece
- Kumari, R., Sahu, M. K., Tripathy, A., Uthansingh, K., & Behera, M. (2018). Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepatic oncology, 5(2), p.HEP08.
- Masetti, C., Lionetti, R., Lupo, M., Siciliano, M., Giannelli, V., Ponziani, F. R., Teti, E., DellUnto, C., Francioso, S., & Brega, A. et al., (2018). Lack of reduction of serum alpha fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv related cirrhosis. J. Viral Hepat.
- Nault, J. C., Sutter, O., & Nahon, P. et al, (2017). Percutaneous Treatment of Hepatocellular Carcinoma: State of the Art and Innovations, Journal of Hepatology, France, vol (68), page (783-797)
- Olthoff, K. M., Forner, A., Hubscher, S., Fung, J. (2011). Liver Transplantation, 17. S26-S33
- Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., & Ferlay, J. et al., (2019). International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer.
- Ross, R. K., Yuan, J. M., & Yu, M. C. et al., (1992). Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet
- Shearn, C. T., & Petersen, D. R. (2015). Understanding the tumor suppressor PTEN in chronic alcoholism and hepatocellular carcinoma. Adv Exp Med Biol
- Sun, C. A., Wu, D. M., Lin, C. C. et al., (2003). Incidence and cofactors of hepatitis C virus- related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol
- Valery, P. C., Laversanne, M., Clark, P. J., Petrick, J. L., McGlynn, K. A., & Bray, F. (2018). Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology 67, 600- 611
- Villanueva, A., & Llovet, J. M. (2011). Targeted therapies for hepatocellular carcinoma. Gastroenterology
- Yang, H. I., Lu, S. N., & Liaw, Y. F. et al., (2002). Hepatitis B e antigen and the risk of hepatocellular carcinoma.
- Yuan, J. M., Govindarajan, S., Arakawa, K. (et al.,) (2004). Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer
Cite this article
-
APA : Sani, A., Khalil-ur-Rehman, M., & Raza, A. S. (2021). Hepatocellular Carcinoma: From Epidemiology to Advancement in Treatment. Global Immunological & Infectious Diseases Review, VI(II), 34-46. https://doi.org/10.31703/giidr.2021(VI-II).05
-
CHICAGO : Sani, Amber, M. Khalil-ur-Rehman, and Aqsa Saleem Raza. 2021. "Hepatocellular Carcinoma: From Epidemiology to Advancement in Treatment." Global Immunological & Infectious Diseases Review, VI (II): 34-46 doi: 10.31703/giidr.2021(VI-II).05
-
HARVARD : SANI, A., KHALIL-UR-REHMAN, M. & RAZA, A. S. 2021. Hepatocellular Carcinoma: From Epidemiology to Advancement in Treatment. Global Immunological & Infectious Diseases Review, VI, 34-46.
-
MHRA : Sani, Amber, M. Khalil-ur-Rehman, and Aqsa Saleem Raza. 2021. "Hepatocellular Carcinoma: From Epidemiology to Advancement in Treatment." Global Immunological & Infectious Diseases Review, VI: 34-46
-
MLA : Sani, Amber, M. Khalil-ur-Rehman, and Aqsa Saleem Raza. "Hepatocellular Carcinoma: From Epidemiology to Advancement in Treatment." Global Immunological & Infectious Diseases Review, VI.II (2021): 34-46 Print.
-
OXFORD : Sani, Amber, Khalil-ur-Rehman, M., and Raza, Aqsa Saleem (2021), "Hepatocellular Carcinoma: From Epidemiology to Advancement in Treatment", Global Immunological & Infectious Diseases Review, VI (II), 34-46
-
TURABIAN : Sani, Amber, M. Khalil-ur-Rehman, and Aqsa Saleem Raza. "Hepatocellular Carcinoma: From Epidemiology to Advancement in Treatment." Global Immunological & Infectious Diseases Review VI, no. II (2021): 34-46. https://doi.org/10.31703/giidr.2021(VI-II).05